EGFR and neoplasm: Besides the blockade of the EGFR–ligand interaction on tumor cells, therapeutic mAbs can also interact with natural killer (NK) cells triggering antibody-dependent cell-mediated cytotoxicity (ADCC) (8–10), and this can translate into superior antitumor effects (11).